Semaglutide is a Glucagon Like Peptide GLP agonist, Semaglutide has been
shown to be effective in inducing weight loss in patients with obesity.
Studies have shown that the infusion of GLP 1 results in reduced
gastrointestinal emptying and an increased rate of fasting and
postprandial gastric volumes, resulting in a decrease in hepatic
glycemia. Polycystic ovarian syndrome (PCOS) is the most common
endocrine disorder among women of reproductive age, Semaglutide affects
the brain’s hunger control centers, causing a reduction in food intake
and an increased feeling of fullness, that is helpful in people who are
struggling to lose weight. Multiple trials have shown that introduction
of Semaglutide in regime helps with weight loss in patients of PCOD and
is also effective in management of insulin resistance and lowering high
levels of VLDL, LDL and triglycerides. Possible introduction of
Semaglutide in the treatment of PCOD and obesity should be considered.